ArticleCellular and molecular life sciences : CMLS2026
Anti-endoglin monoclonal antibody TRC105 prevents the increase of liver inflammatory biomarkers in a mouse model of cholestasis.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholestatic liver diseases are characterized by impaired bile flow, leading to inflammation and progression to cirrhosis and liver failure. Endoglin (ENG), a TGF-β co-receptor, regulates SMAD-dependent signalling and endothelial function. Carotuximab (TRC105) is an anti-ENG monoclonal antibody that binds to ENG. We hypothesized that treatment with TRC105 could prevent the upregulation of inflammatory biomarkers reflecting the activation of liver sinusoidal endothelial cells (LSECs) and hepatic inflammation during the progression of intrahepatic cholestasis (IC) in vivo by modulating the ENG and SMAD signaling pathways. IC was induced in male C57BL/6J mice by feeding with a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for 4 weeks. 18 mice were divided into three groups: a control group (chow diet), an IC group (DDC diet), and a rescue group (DDC diet + TRC105). The rescue group received TRC105 (15 mg/kg) twice weekly throughout the 4 weeks. We observed an inflammation in LSECs and the liver in IC animals characterized by overexpression of p65 NF-κB, ICAM-1, VCAM-1, endothelin-1, Galectin-3, CD11b, Ccl2, Ly6c, Il-1β, and Tnf-α, together with reduced expression of ENG and p-eNOS. TRC105 treatment prevented the downregulation of ENG and p-eNOS, the overexpression of inflammatory biomarkers, and the imbalance of SMAD signalling. We demonstrate for the first time that TRC105 prevents the upregulation of inflammatory biomarkers reflecting LSECs activation and hepatic inflammation, modulates ENG expression, and prevents the imbalance of the SMADs signalling during IC. These findings position ENG as a promising pharmacological target for alleviating inflammation in cholestatic liver disease, thereby opening a new avenue for translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.